Actinomadura Patents (Class 435/825)
  • Patent number: 8329422
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTERĀ® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 11, 2012
    Assignee: Veridex LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Patent number: 7030097
    Abstract: One aspect of the present invention relates to a nucleic acid delivery system including a polymeric structure formed of a biocompatible polymer and a mixture comprising one or more nucleic acid molecules and a first co-dispersant, the mixture being contained within the polymeric structure, wherein the first co-dispersant is present in an amount effective to control diffusion of the one or more nucleic acid from the polymeric structure. Compositions including the nucleic acid delivery system and a pharmaceutically-acceptable carrier are disclosed. Methods of making the nucleic acid delivery system and their use in delivering nucleic acid into a patient and modifying gene expression in a target cell are also disclosed.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 18, 2006
    Assignee: Cornell Research Foundation, Inc.
    Inventors: William Mark Saltzman, Dan Luo, Hong Shen, Kim Woodrow-Mumford, Nadya D. Belcheva
  • Patent number: 6806070
    Abstract: Use of an extract of bacterium from the family Pseudomonadaceae in the production of cosmetic compositions in particular for combating ageing of the skin.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: October 19, 2004
    Assignee: L'Oreal
    Inventors: Richard Martin, Pascal Hilaire, Nathalie Pineau, Lionel Breton
  • Patent number: 6566120
    Abstract: A method for converting compactin to pravastatin is described. Compactin is provided and contacted with an agent derived from Actinomadura under conditions in which the agent converts compactin to pravastatin. Also described are an Actinomadura strain, an Actinomadura cell free extract, an Actinomadura hydroxylase, and a method for lowering cholesterol levels in mammals.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: May 20, 2003
    Assignee: Massachusetts Institute of Technology
    Inventors: Arnold L. Demain, Yulin Peng, Jacob Yashphe, Joseph Davis
  • Patent number: 6017894
    Abstract: Three novel macrolactam monosaccharides isolated from an antimicrobial complex 510 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. uruguayensis ATCC 53713.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: January 25, 2000
    Assignee: Schering Corporation
    Inventors: Raymond Cooper, Ann C. Horan, Mahesh G. Patel, Imbi Truumees, Raymond F. Yarborough
  • Patent number: 5919671
    Abstract: The present invention relates to the novel antitumor antibiotic designated BMS-199687 and to its preparation. The compound is obtained by culturing a new strain of Actinomadura ferruginea. BMS-199687 demonstrates antitumor activity in standard antitumor animal model systems.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: July 6, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mitsuaki Tsunakawa, Li-Ping Chang, Stephen W. Mamber, Isia Bursuker, Robert Hugill
  • Patent number: 5891727
    Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53676. This novel antibiotic is useful as an anticoccidial in chickens and as a growth promotant in cattle and swine.
    Type: Grant
    Filed: March 11, 1992
    Date of Patent: April 6, 1999
    Assignee: Pfizer Inc.
    Inventors: John P. Dirlam, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 5837691
    Abstract: A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura vulgaris subsp. vulgaris ATCC 53748.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: November 17, 1998
    Assignee: Schering Corporation
    Inventors: Vinod R. Hegde, Ann C. Horan, Mahesh G. Patel, Ingrid-Agneta Gunnarsson
  • Patent number: 5534420
    Abstract: New glycopeptides prepared by biotransformation of a vancomycin-type antibiotic by an Acinomadura citrea culture (NRRL 18382), which are useful intermediates, and methods of preparing the biotransformed intermediates by adding a vancomycin-type glycopeptide to a growing culture of Actinomadura citrea NRRL 18382 and continuing fermentation under submerged aerobic conditions, are provided.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: July 9, 1996
    Assignee: Eli Lilly and Company
    Inventors: Manuel Debono, Robert M. Logan, Gary G. Marconi, R. Michael Molloy, Milton J. Zmijewski, Jr.
  • Patent number: 5403738
    Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53764. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: April 4, 1995
    Assignee: Pfizer Inc.
    Inventors: John P. Dirlam, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 5378463
    Abstract: A certain fermentation product of Actinomadura strain Q473-8 yield, when suitably treated, a novel compound having both antibiotic and antitumor activities.
    Type: Grant
    Filed: October 25, 1993
    Date of Patent: January 3, 1995
    Assignee: Bristol Myers Squibb Co.
    Inventors: Daniel R. Schroeder, Kin S. Lam, Jacqueline M. Veitch
  • Patent number: 5374552
    Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: December 20, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Yoichiro Saitoh, Seikichi Kobaru
  • Patent number: 5304373
    Abstract: A certain fermentation product of Actinomadura strain Q473-8 yields, when suitably treated, a novel compound having both antibiotic and antitumor activities.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: April 19, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Daniel R. Schroeder, Kin S. Lam, Jacqueline M. Veitch
  • Patent number: 5281417
    Abstract: A certain fermentation product of Actinomadura strain Q473-8 yields, when suitably treated, a novel compound having both antibiotic and antitumor activities.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: January 25, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel R. Schroeder, Kin S. Lam, Jacqueline M. Veitch
  • Patent number: 5278053
    Abstract: Improved processes for producing a polyether antibiotic compound represented by A82810 comprising: (1) cultivating Actinomadura fibrosa sp. nov. NRRL 18348 or Actinomadura sp. NRRL 18880, (2) feeding acid hydrolyzed casein at a rate from about 2.50-7.50 gm/L/day, (3) feeding glucose at a rate from about 2.50-7.50 gm/L/day, and (4) feeding propionate at a rate from about 0.50-1.5 gm/L/day to the appropriate culture medium during fermentation, are provided.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: January 11, 1994
    Assignee: Eli Lilly and Company
    Inventor: LaVerne D. Boeck
  • Patent number: 5256548
    Abstract: There is provided a new antiviral antibiotic designated herein as BU-4344V which is produced by fermentation of a BU-4344V-producing strain of a new microorganism, Actinomadura parvosata subsp. kistnae ATCC No. 55076. Antibiotic BU-4344V is recovered and purified from the fermentation broth by use of extraction, chromatography, and crystallization techniques. BU-4344V has been found to have some antibacterial activity and inhibits the growth of viruses, including influenza virus type A.
    Type: Grant
    Filed: April 27, 1992
    Date of Patent: October 26, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Masahisa Oka, Koji Tomita, Osamu Tenmyo, Nobuaki Naruse
  • Patent number: 5246830
    Abstract: An enzymatic process for the determination of .beta.-lactam antibiotics in a biological liquid, comprising the steps of (1) incubating the liquid with soluble D-alanyl-D-alanine-carboxypeptidase produce by Actinomadura R39, the .beta.-lactam antibiotic reacting with the enzyme to form an inactive and equimolecular enzyme-antibiotic complex; (2) incubating the mixture obtained with a solution of a thioester substrate having the formula ##STR1## wherein R.sub.1 =benzoyl, phenylacetyl or N.sup..alpha. -acetyl-L-lysyl,R.sub.2 =glycyl or D-alanyl, andR.sub.3 =hydrogen or methylso as to form, by hydrolysis, a 2-mercaptoalkanoic acid having the formula ##STR2## in an amount proportional to the residual enzymatic activity, said incubation being further conducted in the presence of glycine or of a D-amino acid; (3) determining the amount of 2-mercaptoalkanoic acid formed, and (4) comparing the determination of step (3) with a standard, to obtain the antibiotic concentration in the biological liquid.
    Type: Grant
    Filed: April 26, 1991
    Date of Patent: September 21, 1993
    Assignee: Ucb Bioproducts, S.A.
    Inventors: Jacques Degelaen, Jean-Marie Frere
  • Patent number: 5217877
    Abstract: The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: June 8, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Tomokazu Ueki, Takashi Tsuno, Toshikazu Oki
  • Patent number: 5194371
    Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
    Type: Grant
    Filed: July 31, 1991
    Date of Patent: March 16, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Kyoichiro Saitoh, Seikichi Kobaru
  • Patent number: 5189015
    Abstract: A method for prophylactic treatments of the colonization of a Staphylococcus aureus bacterial strain having the ability to bind to fibronectin in a mammal. The method comprises administering a prophylactic therapeutically active amount of a protein having fibronectin binding properties to a mammal in need of such treatment. The generation of infections, such as mastitis, caused by a Staphylococcus aureus bacterial strain are thereby prevented. The administration may be via vaccination to induce immunization.
    Type: Grant
    Filed: December 5, 1991
    Date of Patent: February 23, 1993
    Assignee: Alfa-Laval Agri International AB
    Inventors: Magnus Hook, Kjell M. Lindberg, Torkel M. Wadstrom
  • Patent number: 5183758
    Abstract: An antibiotic complex is produced by the microorganism, Actinomadura brunnea NRRL 15216, ATCC 39216. A novel antibiotic 7-chloro-8-methoxy-2'-N-methyltetracycline, isolated from the antibiotic complex, is active against gram-positive and gram-negative aerobes.
    Type: Grant
    Filed: May 23, 1990
    Date of Patent: February 2, 1993
    Assignee: Schering Corporation
    Inventor: Ann C. Horan
  • Patent number: 5147858
    Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53676. This novel antibiotic is useful as an anticoccidial in chickens and as a growth promotant in cattle and swine.
    Type: Grant
    Filed: April 16, 1990
    Date of Patent: September 15, 1992
    Assignee: Pfizer Inc
    Inventors: John P. Dirlam, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 5145779
    Abstract: Biodegradation of deradeable plastic polyethylene by lignin degrading microorganisms.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: September 8, 1992
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Anthony L. Pometto, III, Byungtae Lee
  • Patent number: 5140101
    Abstract: There is provided a new antiviral antibiotic designated herein as BU-4344V which is produced by fermentation of a BU-4344V-producing strain of a new microorganism, Actinomadura parvosata subsp. kistnae ATCC No. 55076. Antibiotic BU-4344V is recovered and purified from the fermentation broth by use of extraction, chromatography, and crystallization techniques. BU-4344V has been found to have some antibacterial activity and inhibits the growth of viruses, including influenza virus type A.
    Type: Grant
    Filed: November 21, 1990
    Date of Patent: August 18, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Masahisa Oka, Koji Tomita, Osamu Tenmyo, Nobuaki Naruse
  • Patent number: 5114857
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: May 19, 1992
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5098834
    Abstract: New Polyether antibiotic A82810, its acyl and alkyl ester, acyl ester and urethane derivatives, and salts thereof, are useful antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A82810 by culture of Actinomodura fibrosa sp. nov. NRRL 18348 and synergistic compositions of the A82810 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and metichlorpindol are also provided.
    Type: Grant
    Filed: April 10, 1989
    Date of Patent: March 24, 1992
    Assignee: Eli Lilly and Company
    Inventors: Robert L. Hamill, Raymond C. Yao
  • Patent number: 5096817
    Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.
    Type: Grant
    Filed: December 14, 1990
    Date of Patent: March 17, 1992
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5087567
    Abstract: An antitumor antibiotic designated BMY-42428 is produced by fermentation of Actinomadura madurae ATCC-53806. The BMY-42428 antibiotic exhibits both antimicrobial and antitumor activities.
    Type: Grant
    Filed: January 12, 1990
    Date of Patent: February 11, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas T. Dabrah, Grace A. Hesler, Sandra J. Hofstead, Kin S. Lam, Jacqueline M. Mattei, Daniel R. Schroeder, Koji Tomita
  • Patent number: 5061624
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: October 29, 1991
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5024950
    Abstract: A macrolactam disaccharide isolated from an antimicrobial complex 530 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. indica ATCC 53714.
    Type: Grant
    Filed: January 3, 1990
    Date of Patent: June 18, 1991
    Assignee: Schering Corporation
    Inventor: Ann C Horan
  • Patent number: 4992425
    Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.
    Type: Grant
    Filed: June 7, 1988
    Date of Patent: February 12, 1991
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
  • Patent number: 4992423
    Abstract: A new acidic polycyclic ether antibiotic UK-58,852 has the formula: ##STR1## wherein R and R.sup.1 are both hydrogen, and can be prepared by the submerged aerobic propagation in aqueous nutrient media of Actinomadura sp. ATCC 39697. The antibiotic and its cationic salts are active against a variety of microorganisms and are effective in controlling coccidiosis, enteritis, swine dysentery and theileriosis as well as being effective in promotion of growth and/or improving efficiency of feed utilization is swine and ruminants. Two minor components, where R is H and R.sup.1 is CH.sub.3 and wherein R and R.sup.1 are both CH.sub.3, have also been isolated from the fermentation.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: February 12, 1991
    Assignee: Pfizer Inc.
    Inventors: Walter P. Cullen, Hiroshi Maeda, John C. Ruddock, Junsuke Tone
  • Patent number: 4990448
    Abstract: A new antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: February 5, 1991
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Minoru Hanada, Yuji Nishiyama
  • Patent number: 4983525
    Abstract: Plasmid DNA was isolated from two Actinomadura species and characterized by mapping the sites of restriction endonuclease cleavages and by calculation of total molecular size.
    Type: Grant
    Filed: July 2, 1987
    Date of Patent: January 8, 1991
    Assignee: American Cyanamid Company
    Inventors: Jerald S. Feitelson, William M. Maiese
  • Patent number: 4904644
    Abstract: A macrolactam disaccharide isolated from an antimicrobial complex 530 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. indica ATCC 53714.
    Type: Grant
    Filed: August 3, 1988
    Date of Patent: February 27, 1990
    Assignee: Schering Corporation
    Inventors: Vinod R. Hedge, Ann C. Horan, Arthur H. King, Frank A. Gentile, Mahesh G. Patel, Gerald H. Wagman
  • Patent number: 4859598
    Abstract: Antibiotic LL-D42067.beta. derived by aerobic fermentation of the microorganism Actinomadura madurae subspecies simaoensis NRRL 15734, useful as an antibacterial and antiparasitic agent.
    Type: Grant
    Filed: January 21, 1986
    Date of Patent: August 22, 1989
    Assignee: American Cyanamid Company
    Inventors: Guy T. Carter, Donald B. Borders, Joseph J. Goodman, David P. Labeda
  • Patent number: 4780416
    Abstract: The actinomycete "Actinomadura sp." designated in our culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification as are instructions for fermenting aqueous nutrient media with it to produce the BBM 928 antibiotic complex. The BBM 928 complex has utility as an antibacterial agent against gram-positive and acid fast bacteria and exhibits antitumor activity against experimental animal tumors.
    Type: Grant
    Filed: December 18, 1986
    Date of Patent: October 25, 1988
    Assignee: Bristol-Myers Company
    Inventors: Hideo Koshiyama, Fumihide Sakai, Hiroaki Ohkuma
  • Patent number: 4774184
    Abstract: The invention is a process for the production by fermentation of the antibacterial and antiparasitic agents designated LL-D42067.alpha., to methods for its recovery and concentration from crude solutions and to processes for its purification. The invention includes within its scope the biologically pure culture of the antibiotic.
    Type: Grant
    Filed: August 14, 1985
    Date of Patent: September 27, 1988
    Assignee: American Cyanamid Company
    Inventors: Taikwang M. Lee, Donald B. Borders, Joseph J. Goodman, Raymond T. Testa, William M. Maiese, David P. Labeda
  • Patent number: 4708936
    Abstract: Process for the continuous production of L-carnitine by the microbiological method. A microorganism of the strain DSM No. 3225 (HK 1331b) type is cultivated in a bioreactor with crotonobetaine and/or .gamma.-butyrobetaine in the presence of a growth substrate. The culture fluid passes outside of the bioreactor in a circulation in which a separation of the cell is carried out. A quantity of cell-free solution, which is as large as the amount fed to the bioreactor as a substrate, is withdrawn from the bioreactor. The L-carnitine is separated from the cell-free solution.
    Type: Grant
    Filed: March 29, 1985
    Date of Patent: November 24, 1987
    Assignee: Lonza Ltd.
    Inventors: Hans Kulla, Pavel Lehky, Armand Squaratti
  • Patent number: 4683201
    Abstract: New polyether antibiotic A80190, its acyl and alkyl ester, acyl ester and urethane derivatives, and salts thereof, are useful antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80190 by culture of Actinomadura oligospora NRRL 15877 and synergistic compositions of the A80190 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and metichlorpindol are also provided.
    Type: Grant
    Filed: October 15, 1985
    Date of Patent: July 28, 1987
    Assignee: Eli Lilly and Company
    Inventors: Robert L. Hamill, Raymond C. Yao
  • Patent number: 4683204
    Abstract: Improved fermentation process for producing the polyether antibiotic A80190 which comprises cultivating a new strain of Actinomodura Oligospora, NRRL 15878, and the biologically purified culture of this microorganism are provided.
    Type: Grant
    Filed: October 9, 1984
    Date of Patent: July 28, 1987
    Assignee: Eli Lilly and Company
    Inventor: LaVerne D. Boeck
  • Patent number: 4673637
    Abstract: A novel method of urine specimen preparation comprising intense centrifugation and a lipid wash mitigates or prevents loss of bacteria-containing sediment prior to examination. Modifications of the method facilitate examination of urines with interfering constituents such as glucose, phosphates, and soluble and insoluble proteins. By this method, bacteria have been found in the urine of patients suffering from rheumatoid arthritis and essential hypertension. These bacteria were not detected in standard urine preparations. Administration of antibiotic agents effective against the bacteria detected, such as clindamycin, destroyed these bacteria and provided therapeutic relief.
    Type: Grant
    Filed: April 23, 1984
    Date of Patent: June 16, 1987
    Inventor: Edward S. Hyman
  • Patent number: 4631256
    Abstract: BBM-928 is a mixture of antitumor antibacterial substances produced by fermentation of Actinomadura sp., ATCC No. 31491, under controlled conditions. The components may be separated by silica gel thin layer chromatography and by other means.
    Type: Grant
    Filed: October 6, 1983
    Date of Patent: December 23, 1986
    Assignee: Bristol-Myers Company
    Inventors: Hideo Koshiyama, Fumihide Sakai, Hiroaki Ohkuma
  • Patent number: 4615975
    Abstract: A purified isolate of Actinomadura verrucaspora subspecies veractimycin is capable of producing a complex of sulfur-containing antibiotic compounds having anti-tumor activity in recoverable amounts when cultivated under aerobic conditions in a culture medium containing assimilable sources of carbon, nitrogen, and sulfur.
    Type: Grant
    Filed: October 29, 1984
    Date of Patent: October 7, 1986
    Assignee: Warner-Lambert Company
    Inventor: Josefino B. Tunac
  • Patent number: 4578271
    Abstract: Novel compounds designated as WS 6049-A and WS 6049-B are disclosed, as well as compositions containing the compounds thereof, a method of treating microbial infections, a method of prolonging the survival time of the patient with lymphocytic leukemia by administering the compounds thereof, and a process for making the WS 6049 substances, are disclosed. As indicated above, the novel compounds have antimicrobial and antileukemic activities which make them useful against a variety of pathogenic microorganisms and leukemic tumors.
    Type: Grant
    Filed: May 3, 1983
    Date of Patent: March 25, 1986
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Sumio Kiyoto, Motoaki Nishikawa, Morita Iwami, Hiroshi Terano, Masanobu Kohsaka
  • Patent number: 4546084
    Abstract: A biologically pure culture of Actinomadura Sp. Strain H710-49 (ATCC 39144) is provided. The antibiotic designated BBM-1644 may be produced by fermentation of the subject culture.
    Type: Grant
    Filed: April 9, 1984
    Date of Patent: October 8, 1985
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Fumihide Sakai, Takeo Miyaki, Hiroshi Kawaguchi
  • Patent number: 4407946
    Abstract: This invention relates to a novel process for the production of antibiotic X-14868A using the novel microorganism Antinomadura yumaense sp. nov.
    Type: Grant
    Filed: October 22, 1981
    Date of Patent: October 4, 1983
    Assignee: American Cyanamid Company
    Inventors: David P. Labeda, John H. E. J. Martin, Joseph J. Goodman
  • Patent number: 4195079
    Abstract: A new polycyclic ether antibiotic produced by a strain of Actinomadura verrucosospora under submerged fermentation conditions is useful in controlling coccidiosis in poultry and in improving feed utilization efficiency in ruminants.
    Type: Grant
    Filed: January 31, 1979
    Date of Patent: March 25, 1980
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, John R. Oscarson, Liang H. Huang, Riichiro Shibakawa, Junsuke Tone